Excessive neutrophil degranulation is a common feature of many inflammatory disorders, including alpha-1 antitrypsin (AAT) deficiency. Our group has demonstrated that phospholipid transfer protein (PLTP) prevents neutrophil degranulation but serine proteases, which AAT inhibits, cleave PLTP in diseased airways. We propose to identify if airway PLTP activity can be restored by AAT augmentation therapy and how PLTP subdues degranulation of neutrophils in AAT deficient subjects. Airway PLTP activity was lower in AAT deficient patients but elevated in the airways of patients on augmentation therapy. Functional AAT protein (from PiMM homozygotes) prevented PLTP cleavage unlike its mutated ZZ variant (PiZZ). PLTP lowered leukotriene B4 induced degranulation of primary, secondary and tertiary granules from neutrophils from both groups (n = 14/group). Neutrophils isolated from Pltp knockout mice have enhance neutrophil degranulation. Both AAT and PLTP reduced neutrophil degranulation and superoxide production, possibly though their inhibition of the Src tyrosine kinase, Hck. Src kinase inhibitors saracatinib and dasatinib reduced neutrophil degranulation and superoxide production. Therefore, AAT protects PLTP from proteolytic cleavage and both AAT and PLTP mediate degranulation, possibly via Hck tyrosine kinase inhibition. Deficiency of AAT could contribute to reduced lung PLTP activity and elevated neutrophil signaling associated with lung disease.
PLTP lowers degranulation rate in neutrophils from AAT competent or deficient subjects. To demonstrate if PLTP could prevent granule release and alter degranulation in neutrophils from AAT deficient subjects, neutrophils were isolated from peripheral blood and exposed to PLTP prior to LTB 4 stimulation (Fig. 2) . Similar to other studies 13, 14 , neutrophils from AAT deficient subjects degranulated more compared to neutrophils from AAT competent subjects, with elevated primary ( Fig. 2a , NE concentration and cathepsin G activity for LTB 4 and Fig. 2b , NE for N-Formylmethionyl-leucyl-phenylalanine (fMLP)), secondary ( Fig. 2c ; lactoferrin and hCAP18) and tertiary ( Fig. 2d; MMP9 ) granules released at a higher rate. Importantly, pretreatment with PLTP reduced degranulation in neutrophils from both PiMM and PiZZ individuals from each granule (Fig. 2) . PLTP was also observed to reduce superoxide (O 2 − ) production both in PiMM and PiZZ subjects ( Fig. 2e ). Therefore, PLTP can reduce the priming of neutrophils and secretion of neutrophil granules both in PiMM and PiZZ subjects.
Loss of PLTP expression enhances degranulation and superoxide production in mouse neutrophils. Since extracellular PLTP can reduce neutrophil degranulation, we investigated whether PLTP expression alters neutrophil degranulation potential. To test this hypothesis, neutrophils from Pltp −/− mice were isolated from bone marrow and stimulated with fMLP. Compared to wild type mice, neutrophils from Pltp −/− mice release greater concentrations of granules, with elevated primary (Fig. 3a ; NE and cathepsin G and Fig. 3b for NE), secondary ( Fig. 3c ; lactoferrin and hCAP18) and tertiary ( Fig. 3d; MMP9) observed. Pretreating neutrophils with AAT protein from PiMM subjects reduced fMLP induced degranulation from both wild type and Pltp −/− neutrophils ( Fig. 3) . AAT from PiZZ subjects did not prevent fMLP induced NE degranulation (Fig. 3b ). PLTP expression was also observed to alter O 2 − production that was reversed upon AAT stimulation (Fig. 3e ). Therefore, loss of PLTP expression enhances neutrophil degranulation.
Neutrophils from Pltp deficient mice has elevated activity of Src kinase Hck. The Src family of tyrosine kinases can regulate the release of granules from fMLP stimulated neutrophils 34 . Here, we investigated whether the activities of Src kinases were contributing to the elevated neutrophil degranulation from Pltp −/− mice and determined whether AAT alters fMLP-mediated Src kinase activation in neutrophils. Neutrophils from SCienTifiC REPORtS | (2018) 8:15394 | DOI:10.1038/s41598-018-33851-8
Pltp −/− mice have greater phosphorylation at the 416-tyrosine site with fMLP stimuli compared to wild type neutrophils, which was reduced upon AAT stimuli ( Fig. 4a ). Treatment with functional AAT directly inhibited p38 phosphorylation upon fMLP stimuli ( Fig. 4a ). Pltp deficiency resulted in elevated p38 phosphorylation that was reversed by AAT ( Fig. 4a ). These p38 changes ( Fig. 4a ) coincided with elevated tyrosine kinase activity of Hck that can regulate p38 31 (Fig. 4b ). Immuno-precipitated products demonstrate equal protein loading for each tyrosine target ( Fig. 4b ).
To determine whether chemical inhibition of Src kinases could reduce neutrophil activation, we investigate neutrophil activation in the presence of the two Src kinase inhibitors saracatinib or dasatinib. Saracatinib inhibits Src and Bcr-Abl tyrosine-kinase activity and dasatinib blocks Src and Bcr-Abl tyrosine-kinases, c-KIT, EPHA2, and PDGFRβ. Both saracatinib or dasatinib treatment reduced fMLP induced Src and p38 activation in neutrophils from both wild type and Pltp −/− mice ( Fig. 5a ). Saracatinib or dasatinib also prevented fMLP induced O 2 − production ( Fig. 5b ) and degranulation, observed by NE and cathepsin G release ( Fig. 5c ). These data demonstrate targets of saracatinib or dasatinib, at least partially, regulate neutrophil degranulation and AAT and PLTP both reduced Src kinase activities.
Discussion
In the present study, we show that PLTP activity is reduced in AAT deficient airways but is similar to normal baseline levels when subjects are receiving AAT therapy. This is likely due to the PiMM form of AAT preventing proteolytic cleavage of PLTP, unlike the mutated PiZZ form. PLTP can also directly prevent neutrophil superoxide production and degranulation from both PiMM and PiZZ donors. Neutrophils from Pltp −/− mice degranulate at a greater rate than cells from wild type animals. Similar to wild type mice, neutrophils from Pltp −/− mice are sensitive to AAT treatment. Both AAT and PLTP target the deactivation of Src kinase family member, Hck, to reduce neutrophil superoxide production and degranulation ( Fig. 6 ). AAT also prevents activation of other Src kinase family members, Fgr and Lyn. Therefore, this study demonstrates that AAT protects PLTP from degradation and loss of activity, which aids in reducing neutrophil associated inflammation and protease responses.
PLTP activity and gene expression can be regulated by many factors, including a high-fat-cholesterol diet, LPS injection 35 , glucose 36 , insulin 37 and diacylglyceride 38 . The PLTP promoter contains farnesoid X-activated receptor (FXR), liver X receptor (LXR) and peroxisome proliferator-activated receptor (PPAR) binding motifs and show five consensus sequences for the transcription factors Sp1 and AP2 required for PLTP transcription 39, 40 . Hypoxia induces PLTP gene expression in lung cells 24 , but PLTP activity is reduced in COPD airways due to proteolytic cleavage by serine proteases 15 . Protease release is elevated in COPD lungs but become exaggerated at the time of an exacerbation. Upon infection, lung protease activity is elevated and proteins required for microbial clearance and normal lung function are subjected to enhanced degradation 41 . This is further relevant to this study, as PLTP prevents bacterial growth observed in sepsis 42 and PLTP activity has a strong correlation with lung function in COPD subjects 15 . Here, we show that the PiZZ form of AAT is less efficient at preventing PLTP cleavage than the PiMM form and PLTP has important anti-inflammatory properties against neutrophils from both AAT deficient and competent individuals. Loss of PLTP expression heightens neutrophil superoxide production and degranulation upon stimulation. Therefore, PLTP expression and activity can be modulated by multiple factors but the disease lung microenvironment in AAT deficiency is not favorable for PLTP integrity and activity.
Neutrophils play a critical role in the host defense, but enhanced activation can significantly contribute to tissue damage during autoimmune and inflammatory diseases, such as AAT deficiency. Determining how PLTP and AAT keep the neutrophil in a basal state is critical to understanding the elevated inflammation observed in AAT deficient subjects. Neutrophils do generate and release AAT that could contribute to protease inhibition, with AAT from deficient individuals less efficient at inhibiting proteases 43 . This may also contribute to neutrophil degranulation, as neutrophils from AAT deficient subjects degranulation at a higher frequency than neutrophils from AAT competent subjects 13 . It was surprising that PLTP and AAT appear to have overlapping roles in preventing inflammation, with both proteins targeting Hck kinase activity. However, AAT also inhibited the activities of two other Src kinases family members, Fgr and Lyn, which may further enhance its anti-inflammatory abilities. Neutrophils from Hck −/− Fgr −/− animals have reduced degranulation 44 and fail to activate a respiratory burst and display reduced F-actin polymerization upon fMLP stimuli 31 . Lyn, Fgr and Hck deficiency has no effect on leukocyte migration but do significantly contribute to inflammation via immune cell activation 32 . Importantly, constitutive activation of Hck in mice leads to the development of an emphysema like phenotype with some pulmonary fibrosis with inflammation that altered lung function and respiratory distress in older animals 45 . Despite fibrosis being rarely documented in AAT deficient subjects, there are reported cases of AAT deficient patients being more susceptible to interstitial lung diseases 46 . Whether PLTP modulates leukocyte migration requires exploring. It should be noted that PLTP and AAT could also interact with multiple other signaling to minimize neutrophil responses, such as G-protein-coupled chemokine/chemoattractant receptors, Fc-receptors, adhesion receptors, TLRs and C-type lectins. These and other potential pathways, in terms of PLTP and AAT signaling, need to be examined in future studies.
Our group have previously demonstrated that saracatinib treatment had protective effects in animal and cell models of cigarette smoke induced COPD 47 . High dosing of saracatinib has been reported to yield several cases of neutropenia in cancer patients 48 . Dasatinib is reported not to affect migration, phagocytosis or killing of bacteria by neutrophils 49 . However, dasatinib does prevent adhesion of human neutrophils in the presence of whole serum 49 and also prevents TLR ligand induction of TNF-α signaling 50 . Therefore, inhibition of Src family kinases could prevent unnecessary inflammation that contributes to tissue damage, without reducing microbial clearance. However, further studies are required to determine the effect of Src inhibitors on additional neutrophil functions.
There are several proteins that bind to PLTP, including ABCA1, apoA1 and apoA2. Similar to PLTP, ABCA1 and apoA1 both have anti-inflammation abilities 51 . ABCA1 is a cell membrane protein that exports excess cholesterol from cells to apoAI, the major protein in HDLs. The interaction of apoAI with ABCA1 suppresses LPS-induced IL-1β, IL-6, and TNF-α 51 . Importantly, PLTP regulates the size and composition of HDL in the . Neutrophils from Pltp deficient mice has elevated tyrosine kinase activity of Hck. Neutrophils were collected from C57BL/6 and Pltp −/− mice. Neutrophils were exposed to AAT prior to fMLP at 37 °C for 5 minutes. Immunoblots were performed for (a) phosphorylated Src kinase family (Tyr416) and total Hck, Fgr, Lyn, phosphorylated and total p38, and β-Actin. Densitometry was performed for p-p38 and p-Src. (b) HCK, Fgr and Lyn were immunoprecipitated and tyrosine kinases activity assays and immunoblots were performed with the IP product. Data is represented as relative activity, corrected to absorbance for the wild type non-treated neutrophil group. N = 6 animal per group. Each measurement is the mean ± SEM. *Denotes a p value < 0.05, when comparing both treatments connected by a line, determined by 2-way ANOVA with Tukey's post hoc test. circulation and plays an important role in controlling plasma HDL levels 52 . AAT is also present in HDL 53 but little is known about the role of AAT in HDL and the subsequent role of PLTP on the circulation of AAT in HDL. Inflammation reduces the concentration of HDL and possibly compromises its function 54 . AAT presence in HDL impacts on inflammation and emphysema formation 55 . Interestingly AAT containing HDL prevents neutrophil and macrophage infiltration into the airways and reduces elastase-induced production of IL-6, MCP-1, TNF-α, MMP-2 and MMP-9 55 . However due to the interactions of PLTP with ABCA1 and HDL, and the protective role of AAT on PLTP, investigating PLTP binding proteins would be of great interest. ApoA1 and ABCA1 has also be implicated in mediating neutrophil inflammation in asthma 56 and ApoA1 decreases neutrophil degranulation and superoxide production 57 . Therefore, ABCA1 and ApoA1 could interact with PLTP and AAT to influence their anti-inflammatory potential.
There are several limitations that need to be discussed here. Firstly, we compare changes in human and mouse neutrophil degranulation. The frequency of neutrophils in mice is less compared to humans. Mice have many different receptors and several of their granule content differ to humans 58 . Mice do not express FcαRI 59 , which plays several important roles in human neutrophils, such as oxidative burst, cytokine release, and phagocytosis. Therefore, it is important to consider the possibility that the neutrophil degranulation responses may not occur in precisely the same way in humans and mice. Recently, loss of the mouse Serapina1 genes was shown to result in age dependent emphysema in a similar manner to the human disease 60 , which suggests that the mouse still represents a useful model for AAT deficiency. Secondly, we primarily focus on neutrophil degranulation and not on other neutrophil functions. The role of PLTP on chemotaxis, NETosis and phagocytosis needs to be addressed in future studies. Third, the role of Hck and other Src kinases in AAT deficiency requires further investigating prior to exploring the potential of these inhibitors in the human disease. Fourth, we use higher biological levels of PLTP (0.5 µM versus 0.23 μM) 61 to treat neutrophils, as the rPLTP utilized here for the human samples is less active than corresponding concentrations of PLTP activity in plasma ( Supplementary Fig. S1 ). The AAT levels used here (2 µM) are lower than plasma (ranging from 20-39 µM) but within range of lung concentrations (2 µM). Therefore, non-specific effects may be observed with higher total PLTP levels. Fifth, most of the patient population were former smokers, which can alter neutrophil degranulation, inactivate AAT 62 and lead to PLTP inactivation. At the time of blood collect, no patient was an active smoker (Table 1) . Finally, the only difference observed for AAT and PLTP signaling mediating neutrophil degranulation was AAT inhibition of Fgr and Lyn.
In conclusion, PLTP activity diminishes neutrophil activation and degranulation and, similar to AAT, PLTP reduces Hck activity in neutrophils. Reduced PLTP activity in the AAT deficient lungs could leave the lung more susceptible to neutrophil associated inflammation and worsening of disease progression.
Methods
Human samples. BALF was obtained from healthy never smokers with a normal AAT (n = 8) and AAT deficient patients (n = 22) (see Table 1 for demographics). All subjects were free from exacerbation for six months prior to this study. A subset of the PiZZ subjects (n = 8) were receiving AAT augmentation therapy, Zemaira R intravenously, at standard doses (60 mg/kg/week). Blood was drawn and BALF collected 63 . AAT deficiency was determined, using the Grifols AlphaKit test kits processed at the Alpha-1 Antitrypsin Genetics Laboratory at GeneAidyx LLC (Alachua, Florida), by assessing low serum levels, followed by genotyping, phenotyping and sequencing. Written and informed consent was obtained from all study participants and the trial was approved by the institutional review board of the University of Miami School of Medicine, Mount Sinai Icahn School of Medicine and State University of New York Downstate Medical Center. All methods were performed in accordance with the institutional review board guidelines and regulations. PLTP activity and degradation analysis. PLTP activity was measured by using an assay kit (Roar Biomedical, New York, NY), as previously described 64 . Activity was standardized to BALF urea concentrations determined by a commercially available kit (Abnova, Walnut, CA). BALF was concentrated utilizing 3,000 NMWL Centriplus filter devices (Millipore) and PLTP immunoblots were performed to observe PLTP degradation utilizing a rabbit anti-human PLTP polyclonal rabbit antibody (Cat. # NB400-106, Novus Biological, Littleton, CO, USA) that recognizes a partial peptide of human PLTP. Recombinant human PLTP (Novus Biological) was incubated with 1 μM AAT protein (from either a PiMM or PiZZ subject) for one-hour at 37 °C, followed by the addition of 10 μl of BALF (PiZZ subjects) in PBS to a final volume of 20 μl for 24 hours at 37 °C. PLTP degradation was examined by immunoblotting samples and detection with a PLTP antibody.
Isolation of AAT protein from PiMM and PiZZ subjects. Blood was collected from PiMM or PiZZ individuals and AAT was isolated from the serum of AAT deficient (PiZZ) and competent nonsmoker individuals (PiMM) by affinity chromatography using AAT select resin (Cat # 17547201, GE Healthcare, Piscataway, NJ) as previously described 6 Neutrophil degranulation and superoxide production determination. Secreted protein samples from purified neutrophils (2 × 10 7 cells/ml) were examined by ELISA, activity assays and immunoblots. NE levels were determined by ELISA (R&D Systems). Cathepsin G activity was determined in samples with a colorimetric cathepsin G activity assay kit (Abcam, ab126780, Cambridge, MA), as described by manufacturers. Immunoblots were performed with anti-human lactoferrin polyclonal rabbit (immunogen was full length native protein, Cat. # ab15811, Abcam) and anti-human hCAP18 rabbit polyclonal antibodies (Cat. # PA5-20513, Invitrogen). BALF gelatinase activity (MMP9) was determined by gelatin zymography 66 . Densitometry was performed on MMP9 positive bands and represented densitometry units (DU) measured by pixel intensity of bands, using Bio-Rad Laboratories Image Lab software (version 4.0, build 16). Equal cell numbers in each experiment was demonstrated by profiling electrophoretic of whole cell lysates in a Coomassie blue stained gel, i.e. loading control. O 2 − production was quantified by O 2 − dismutase-inhibitable reduction of cytochrome c at 550 nm, as previously described 67 .
Intracellular signaling. Protein was isolated from neutrophils using lysis buffer (10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM PMSF, 0.5 mM DTT, 0.2% Igepal CA-630) and sonication. Immunoblots were conducted on the protein from cells to determine levels of phosphorylated p38(Thr180/Tyr182) (anti-human phosphorylated p38(Thr180/Tyr182) polyclonal rabbit antibody against a synthetic phosphopeptide corresponding to residues surrounding Thr180/Tyr182 of human p38 MAPK; Cat. # 4511), Src(Tyr416) (anti-human polyclonal rabbit antibody against a synthetic phosphopeptide corresponding to residues surrounding Tyr419 of human Src; Cat # 2101) and total protein levels of Hck (anti-human monoclonal rabbit antibody against a synthetic peptide corresponding to residues surrounding Lys60 of human Hck protein; Cat. # 14643), Fgr (anti-human Fgr polyclonal rabbit antibody against a synthetic peptide corresponding to residues close to the amino terminus of human Fgr; Cat. #2755), Lyn (anti-human LIF polyclonal rabbit antibody from the epitope mapping at the N-terminus of Lyn of human origin; Cat. # SC-15, Santa Cruz Biotechnologies), p38 (anti-human p38 polyclonal rabbit antibody against a synthetic peptide corresponding to the sequence of human p38 MAPK; Cat. # 9212), and β-actin (anti-human β-actin polyclonal rabbit antibody against a synthetic peptide corresponding to amino-terminal residues of human β-actin; Cat. # 4967 unless specified all antibodies were from Cell Signaling, Danvers, MA). Uncropped immunoblots are present in Supplementary Figs 2-6 . Src kinase activity was determined as previously described 47 utilizing a tyrosine kinase activity kit (MK410; Takara Bio, Mountain View, CA). Hck, Fgr and Lyn were immune-precipitated from neutrophil protein samples and tyrosine kinase activity was determined as instructed by manufacturers in the tyrosine kinase kit. A positive protein tyrosine kinase control is supplied in this kit. Results are presented as relative activity compared with non-treated wild-type neutrophil protein samples. Immunoblots were performed to confirm positive immune-precipitation. Statistical analyses. Data are expressed as dot plots and bar graphs with the means ± S.E.M highlighted in red. Differences between two groups were compared by Student's t test (two-tailed). Experiments with more than 2 groups were analyzed by ANOVA with Tukey's post hoc test analysis. p values for significance were set at 0.05 and all significant changes were noted with *. All analysis was performed using GraphPad Prism Software (Version 6.0 h for Mac OS X).
